Less is more? STI in acute and chronic HIV-1 infection

被引：40

作者：

Altfeld, M ^{[1
]}

Walker, BD

机构：

[1] Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02114 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

来源：

NATURE MEDICINE | 2001年 / 7卷 / 08期

关键词：

D O I：

10.1038/90901

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Emerging data has indicated that supervised treatment interruption (STI) of highly active antiretroviral therapy might significantly augment immune responses in HIV-1-infected patients and slow disease progression. Here the authors discuss the rationale behind STI and future directions for study.

引用

页码：881 / 884

页数：4

共 54 条

[31] Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men
Lyles, RH
Muñoz, A
Yamashita, TE
Bazmi, H
Detels, R
Rinaldo, CR
Margolick, JB
Phair, JP
Mellors, JW
[J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (03) : 872 - 880
[32] Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection
Malhotra, U
Berrey, MM
Huang, YJ
Markee, J
Brown, DJ
Ap, S
Musey, L
Schacker, T
Corey, L
McElrath, MJ
[J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) : 121 - 131
[33] MARKOWITZ M, 2001, 8 C RETR OPP INF CHI
[34] Cellular immune responses to HIV
McMichael, AJ
Rowland-Jones, SL
[J]. NATURE, 2001, 410 (6831) : 980 - 987
[35] HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors
Migueles, SA
Sabbaghian, MS
Shupert, WL
Bettinotti, MP
Marincola, FM
Martino, L
Hallahan, CW
Selig, SM
Schwartz, D
Sullivan, J
Connors, M
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (06) : 2709 - 2714
[36] Structured treatment interruptions in antiretroviral management of HIV-1
Miller, V
[J]. CURRENT OPINION IN INFECTIOUS DISEASES, 2001, 14 (01) : 29 - 37
[37] Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure
Miller, V
Sabin, C
Hertogs, K
Bloor, S
Martinez-Picado, J
D'Aquila, R
Larder, B
Lutz, T
Gute, P
Weidmann, E
Rabenau, H
Phillips, A
Staszewski, S
[J]. AIDS, 2000, 14 (18) : 2857 - 2867
[38] Structured treatment interruptions to control HIV-1 and limit drug exposure
Montaner, LJ
[J]. TRENDS IN IMMUNOLOGY, 2001, 22 (02) : 92 - 96
[39] HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
Neumann, AU
Tubiana, R
Calvez, V
Robert, C
Li, TS
Agut, H
Autran, B
Katlama, C
[J]. AIDS, 1999, 13 (06) : 677 - 683
[40] Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
Ogg, GS
Jin, X
Bonhoeffer, S
Dunbar, PR
Nowak, MA
Monard, S
Segal, JP
Cao, YZ
Rowland-Jones, SL
Cerundolo, V
Hurley, A
Markowitz, M
Ho, DD
Nixon, DF
McMichael, AJ
[J]. SCIENCE, 1998, 279 (5359) : 2103 - 2106

← 1 2 3 4 5 6 →